Testing will be performed at baseline (SAQ questionnaire, cardiopulmonary testing, resource utilization, metabolomics and vascular testing). This will be repeated on the same group of patients after 3 months of nebivolol treatment.

Testing will be performed at baseline (SAQ questionnaire, cardiopulmonary testing, resource utilization, metabolomics and vascular testing). This will be repeated on the same group of patients after 3 months of nebivolol treatment.
Nebivolol: Patient to start nebivolol and have repeat testing in 3 months

Nebivolol

Sex: Female, Male

Region of Enrollment

Seattle Angina Questionnaire (SAQ):
The SAQ is a 5 part survey that is widely used and well validated tool to assess angina stability and angina frequency among patients with coronary artery disease.
The SAQ is a validated, self-administered 19-item questionnaire with 5 different dimensions of health status in patients with CAD including: angina frequency, angina stability, disease-specific quality of life, physical limitations and treatment satisfaction. Each SAQ domain score ranges from 0-100, with higher scores indicating a better health status.

Testing will be performed at baseline (SAQ questionnaire, cardiopulmonary testing, resource utilization, metabolomics and vascular testing). This will be repeated on the same group of patients after 3 months of nebivolol treatment.
Nebivolol: Patient to start nebivolol and have repeat testing in 3 months
There was a significant improvement in angina stability (p=0.034) post treatment compared to baseline. The other parameter of the SAQ were not statistically different ( physical limitation, angina frequency, treatment satisfaction and quality of life)

Baseline

Seattle Angina Questionnaire Score

Assessment of exercise capacity (peak VO2) as determined by CPET

Peak VO2 Measured by Cardiopulmonary Exercise Testing

Resource utilization as determined by patient phone calls, office visits, emergency room visits, and number of hospitalizations, as well an index cost for any hospitalizations

Testing will be performed at baseline (SAQ questionnaire, cardiopulmonary testing, resource utilization, metabolomics and vascular testing). This will be repeated on the same group of patients after 3 months of nebivolol treatment.
Nebivolol: Patient to start nebivolol and have repeat testing in 3 months
this data was incomplete and not useful for analysis

Resource Utilization Questionnaire

The SF-36v2 is a commonly used instrument to assess HRQoL8. The questionnaire evaluates 8 HRQoL domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The physical component score is a composite of the SF-36v2 physical health domains (physical functioning, role-physical, bodily pain and general health) and the mental component score a composite of the mental health domains (vitality, social functioning, role-emotional and mental health). Each HRQoL domain score ranges from 0 to 100, with higher scores corresponding to a better health status. The SF-36v2 domain scores were calculated using the QualityMetric Health Outcomes Scoring Software version 4.5.

SF36

Assessment of exercise duration as determined by CPET

Exercise Duration

Assessment of peak heart rate as determined by CPET

Peak Heart Rate as Measured by Cardiopulmonary Exercise Testing

peak O2 pulse as measured by cardiopulmonary exercise testing

Peak O2 Pulse

Overall Study

Nandita S. Scott

Microvascular Angina

Patient to start nebivolol and have repeat testing in 3 months

microvascular angina/dyspnea

Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease

Најкомплетната база на податоци за лековити билки поддржана од науката